SLC5A2 and lobular neoplasia: Except for renin angiotensin system inhibitors, the pharmaceutical intervention with sodium-glucose co-transporter-2 (SGLT2) inhibitors has shown SLE-nonspecific effects by altering LN progression affecting non-immune mechanisms.